Soligenix Inc
NASDAQ:SNGX
Intrinsic Value
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. [ Read More ]
The intrinsic value of one SNGX stock under the Base Case scenario is 1.382 USD. Compared to the current market price of 0.427 USD, Soligenix Inc is Undervalued by 69%.
Valuation Backtest
Soligenix Inc
Run backtest to discover the historical profit from buying and selling SNGX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Soligenix Inc
Current Assets | 9.5m |
Cash & Short-Term Investments | 8.4m |
Receivables | 195.2k |
Other Current Assets | 866k |
Non-Current Assets | 290k |
PP&E | 241.8k |
Other Non-Current Assets | 48.3k |
Current Liabilities | 6.2m |
Accounts Payable | 1.1m |
Accrued Liabilities | 2.8m |
Other Current Liabilities | 2.3m |
Non-Current Liabilities | 1.1m |
Long-Term Debt | 1m |
Other Non-Current Liabilities | 111.9k |
Earnings Waterfall
Soligenix Inc
Revenue
|
839.4k
USD
|
Cost of Revenue
|
-742.1k
USD
|
Gross Profit
|
97.3k
USD
|
Operating Expenses
|
-7.8m
USD
|
Operating Income
|
-7.7m
USD
|
Other Expenses
|
1.6m
USD
|
Net Income
|
-6.1m
USD
|
Free Cash Flow Analysis
Soligenix Inc
SNGX Profitability Score
Profitability Due Diligence
Soligenix Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Soligenix Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
SNGX Solvency Score
Solvency Due Diligence
Soligenix Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Soligenix Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SNGX Price Targets Summary
Soligenix Inc
According to Wall Street analysts, the average 1-year price target for SNGX is 3.443 USD with a low forecast of 3.03 USD and a high forecast of 3.938 USD.
Ownership
SNGX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SNGX Price
Soligenix Inc
Average Annual Return | 4.39% |
Standard Deviation of Annual Returns | 66.87% |
Max Drawdown | -99% |
Market Capitalization | 4.4m USD |
Shares Outstanding | 10 524 400 |
Percentage of Shares Shorted | 1.1% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The firm is focused on developing products to treat rare diseases. The firm operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics segments includes developing of HyBryte (SGX301 or synthetic hypericin) a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). Public Health Solutions segment includes RiVax to protect against exposure to ricin toxin vaccine candidate and SGX943 therapeutic candidate for antibiotic resistant and infectious disease. The firm's Development programs include innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, oral mucositis in head and neck cancer, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders including pediatric Crohn's disease (SGX203).
Contact
IPO
Employees
Officers
The intrinsic value of one SNGX stock under the Base Case scenario is 1.382 USD.
Compared to the current market price of 0.427 USD, Soligenix Inc is Undervalued by 69%.